Orthopaedic surgery in severe bleeding disorders: a low-volume, high-cost procedure.

摘要: Summary. As more and nations are scrutinizing their health care costs, attention has been focused on high-cost low-density disease. Assessment of actual total cost for haemophilia its positive outcome becomes essential to justify support these patients. In this study, we assessed hospital diagnosis-related group (DRG) reimbursement patients undergoing elective orthopaedic surgical procedures from May 1999 December 1999. Hospital was by a prospective microcost-analysis method. To identify real performed registration preoperative phase, operative phase 1-year follow-up costs. included personnel costs clinical laboratory procedures, blood products, prosthetic implants, coagulation factor concentrates drugs. These data were compared with DRG reimbursement. We nine consecutive patients, mean age 38 years (19–54 years) who had 10 major during the study period. Six A, two B one VII deficiency. Data analysis showed US$ 54 201 (range US$ 25 795–105 479; 1US$ = 8.5 NOK). The average revenue (50% + income related length stay) $4730 $ 1 308–13 601). Our confirms that surgery in severe bleeding disorders puts considerable expense. Activity-based financing, as used Norway, does not provide proper part care.